Artiva Biotherapeutics, Inc. 4

Director Brian Daniels received a stock option award for 16,250 shares of Artiva Biotherapeutics, Inc. common stock at a $10.42 exercise price on September 10, 2026.

On September 10, 2026, Director Brian Daniels received a stock option award from Artiva Biotherapeutics, Inc. to purchase 16,250 shares of common stock at an exercise price of $10.42 per share, with the option vesting in full on the earlier of September 10, 2027 or the company’s 2027 annual stockholder meeting and expiring on September 9, 2036. This is a routine director compensation grant rather than an open-market purchase or sale, and after this award Daniels holds derivative rights to 16,250 shares, implying an option notional value of approximately $169,000 based on the grant price, while the post-transaction common stock holdings indicated in the filing are 16,250 shares. The transaction reflects standard equity-based compensation and does not signal a discretionary buy or sell in the open market.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-390531

Alert Tier

5